Citation Impact
Citing Papers
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Mir-34: A New Weapon Against Cancer?
2014
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
The DNA-damage response in human biology and disease
2009 StandoutNature
Molecular Imaging of Amyloidosis: Will the Heart Be the Next Target After the Brain?
2011
Myeloid-derived suppressor cells coming of age
2018 Standout
Tumor‐Derived Exosomes in Immunosuppression and Immunotherapy
2020
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Breast cancer
2016 Standout
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
2014
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients
2013
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
Tumor-Derived G-CSF Facilitates Neoplastic Growth through a Granulocytic Myeloid-Derived Suppressor Cell-Dependent Mechanism
2011
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy
2005
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
2003
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
2020
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
2007
Coordinated regulation of myeloid cells by tumours
2012 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
2013 Standout
Multiple myeloma
2000 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Neurologic Complications of Plasma Cell Disorders
2004
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
2011
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
How stem cells age and why this makes us grow old
2007
The DNA Damage Response: Making It Safe to Play with Knives
2010 Standout
Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses
2006
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
2005
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Myeloid-derived Suppressor Cells in Cancer Patients
2012
Recent advances on the role of tumor exosomes in immunosuppression and disease progression
2012
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Systemic amyloidosis
2015 Standout
Prevention of Venous Thromboembolism
2004 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment
2013
Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy
2010
Pathogenesis and treatment of renal failure in multiple myeloma
2008
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Prevention of Venous Thromboembolism
2008 Standout
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
The biogenesis, biology and characterization of circular RNAs
2019 Standout
Clonal evolution in cancer
2012 StandoutNature
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
2018
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
2012
Neutrophils in cancer: neutral no more
2016 Standout
The Hallmarks of Aging
2013 Standout
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Myeloid derived suppressor cells in human diseases
2011
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Reassessment of Exosome Composition
2019 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
2020 Standout
Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies
2018
Cellular senescence: from physiology to pathology
2014 Standout
Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research
2011
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Anti‐IL ‐6 receptor mA b eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T ‐cell responses
2012
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
2018
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
2002
Targeting the bone marrow microenvironment in multiple myeloma
2014
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
2013
Myeloid‐derived suppressor cell heterogeneity in human cancers
2014
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
2012
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Complexity and challenges in defining myeloid-derived suppressor cells
2014
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
2014
Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma
2006
Dauer larva quiescence alters the circuitry of microRNA pathways regulating cell fate progression inC. elegans
2012 StandoutNobel
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
2014 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
2006
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
2014
Oral bisphosphonates
2000
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
A systematic review of the role of bisphosphonates in metastatic disease
2004
Works of Peter Gimsing being referenced
Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group
2006
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
2008
Improved survival of multiple myeloma patients with late relapse after high‐dose treatment and stem cell support, a population‐based study of 348 patients in Denmark in 1994–2004*
2010
Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support
2001
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
2007
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
2010
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
2010
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial
1998
Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature
1999
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
2005
Aberrant microRNA expression in multiple myeloma
2013
Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.
2005
Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
2012
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study
2015
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
2006
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
2017
99mTc-aprotinin scintigraphy in amyloidosis.
2003
Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).
2004
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
2000
Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.
2007
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
2018